-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Shenzhen Haiwang Bioengineering Co., Ltd. announced that its wholly-owned subsidiary, Shenzhen Haiwang Pharmaceutical Science and Technology Research Institute Co., Ltd., in the research of the new anti-tumor drug "xylene sulphate padvance tablets" (acceptance number: IND134903) clinical research application on January 19, 2018 by the United States Food and Drug Administration approved (the "U.S. FDA" ) to allow it to conduct clinical research in the United States.
xylene sulfonate protinib is the first target anti-small cell lung cancer drug in China for the absence of eGFR19 exoon, no. 21 external onset mutation. The announcement indicates that the company has independent intellectual property rights over xylene sulfonate poutini and tablets, and no identical products are currently available in China.
from the similar product market, the foreign-listed same-target drug is Germany's Bollinger Ingham in 2013 listed Gilotrif (Afatini), the domestic has not yet been listed. According to the company's annual report, Gilotrif had global sales of $231 million in 2015.
.